A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer
- Publication type:
- Journal article
- Metadata:
-
- Autoren
- Sanjeev Krishna
- Senthil Ganapathi
- Irina Chis Ster
- Mohamed EM Saeed
- Matt Cowan
- Caroline Finlayson
- Hajnalka Kovacsevics
- Herwig Jansen
- Peter G Kremsner
- Thomas Efferth
- Devinder Kumar
- Autoren-URL
- https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000364156800017&DestLinkType=FullRecord&DestApp=WOS_CPL
- DOI
- 10.1016/j.ebiom.2014.11.010
- Externe Identifier
- Clarivate Analytics Document Solution ID: CV3JZ
- PubMed Identifier: 26137537
- ISSN
- 2352-3964
- Ausgabe der Veröffentlichung
- 1
- Zeitschrift
- EBIOMEDICINE
- Schlüsselwörter
- Colorectal cancer
- Artesunate
- Dihydroartemisinin
- Ki67
- Neutropaenia
- Paginierung
- 82 - 90
- Datum der Veröffentlichung
- 2015
- Status
- Published
- Titel
- A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer
- Sub types
- Article
- Ausgabe der Zeitschrift
- 2
Data source: Web of Science (Lite)
- Other metadata sources:
-
- Autoren
- Sanjeev Krishna
- Senthil Ganapathi
- Irina Chis Ster
- Mohamed EM Saeed
- Matt Cowan
- Caroline Finlayson
- Hajnalka Kovacsevics
- Herwig Jansen
- Peter G Kremsner
- Thomas Efferth
- Devinder Kumar
- DOI
- 10.1016/j.ebiom.2014.11.010
- ISSN
- 2352-3964
- Ausgabe der Veröffentlichung
- 1
- Zeitschrift
- EBioMedicine
- Sprache
- en
- Paginierung
- 82 - 90
- Datum der Veröffentlichung
- 2015
- Status
- Published
- Herausgeber
- Elsevier BV
- Herausgeber URL
- http://dx.doi.org/10.1016/j.ebiom.2014.11.010
- Datum der Datenerfassung
- 2019
- Titel
- A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer
- Ausgabe der Zeitschrift
- 2
Data source: Crossref
- Abstract
- <h4>Background</h4>Artesunate is an antimalarial agent with broad anti-cancer activity in in vitro and animal experiments and case reports. Artesunate has not been studied in rigorous clinical trials for anticancer effects.<h4>Aim</h4>To determine the anticancer effect and tolerability of oral artesunate in colorectal cancer (CRC).<h4>Methods</h4>This was a single centre, randomised, double-blind, placebo-controlled trial. Patients planned for curative resection of biopsy confirmed single primary site CRC were randomised (n = 23) by computer-generated code supplied in opaque envelopes to receive preoperatively either 14 daily doses of oral artesunate (200 mg; n = 12) or placebo (n = 11). The primary outcome measure was the proportion of tumour cells undergoing apoptosis (significant if > 7% showed Tunel staining). Secondary immunohistochemical outcomes assessed these tumour markers: VEGF, EGFR, c-MYC, CD31, Ki67 and p53, and clinical responses.<h4>Findings</h4>20 patients (artesunate = 9, placebo = 11) completed the trial per protocol. Randomization groups were comparable clinically and for tumour characteristics. Apoptosis in > 7% of cells was seen in 67% and 55% of patients in artesunate and placebo groups, respectively. Using Bayesian analysis, the probabilities of an artesunate treatment effect reducing Ki67 and increasing CD31 expression were 0.89 and 0.79, respectively. During a median follow up of 42 months 1 patient in the artesunate and 6 patients in the placebo group developed recurrent CRC.<h4>Interpretation</h4>Artesunate has anti-proliferative properties in CRC and is generally well tolerated.
- Addresses
- Institute of Infection and Immunity, Department of Pathology, United Kingdom.
- Autoren
- Sanjeev Krishna
- Senthil Ganapathi
- Irina Chis Ster
- Mohamed EM Saeed
- Matt Cowan
- Caroline Finlayson
- Hajnalka Kovacsevics
- Herwig Jansen
- Peter G Kremsner
- Thomas Efferth
- Thomas Efferth
- Devinder Kumar
- DOI
- 10.1016/j.ebiom.2014.11.010
- eISSN
- 2352-3964
- Externe Identifier
- PubMed Identifier: 26137537
- PubMed Central ID: PMC4484515
- Funding acknowledgements
- National Research Council, Sudan:
- Open access
- true
- ISSN
- 2352-3964
- Ausgabe der Veröffentlichung
- 1
- Zeitschrift
- EBioMedicine
- Schlüsselwörter
- Humans
- Colorectal Neoplasms
- Artemisinins
- Carcinoembryonic Antigen
- Ki-67 Antigen
- Placebos
- Treatment Outcome
- Immunohistochemistry
- Staining and Labeling
- Administration, Oral
- Survival Analysis
- Pilot Projects
- Double-Blind Method
- Demography
- Aged
- Female
- Male
- Biomarkers, Tumor
- Artesunate
- Sprache
- eng
- Medium
- Electronic-eCollection
- Online publication date
- 2014
- Open access status
- Open Access
- Paginierung
- 82 - 90
- Datum der Veröffentlichung
- 2015
- Status
- Published
- Publisher licence
- CC BY
- Datum der Datenerfassung
- 2015
- Titel
- A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer.
- Sub types
- research-article
- Randomized Controlled Trial
- Journal Article
- Ausgabe der Zeitschrift
- 2
Files
http://www.thelancet.com/article/S2352396414000346/pdf https://europepmc.org/articles/PMC4484515?pdf=render
Data source: Europe PubMed Central
- Abstract
- BACKGROUND: Artesunate is an antimalarial agent with broad anti-cancer activity in in vitro and animal experiments and case reports. Artesunate has not been studied in rigorous clinical trials for anticancer effects. AIM: To determine the anticancer effect and tolerability of oral artesunate in colorectal cancer (CRC). METHODS: This was a single centre, randomised, double-blind, placebo-controlled trial. Patients planned for curative resection of biopsy confirmed single primary site CRC were randomised (n = 23) by computer-generated code supplied in opaque envelopes to receive preoperatively either 14 daily doses of oral artesunate (200 mg; n = 12) or placebo (n = 11). The primary outcome measure was the proportion of tumour cells undergoing apoptosis (significant if > 7% showed Tunel staining). Secondary immunohistochemical outcomes assessed these tumour markers: VEGF, EGFR, c-MYC, CD31, Ki67 and p53, and clinical responses. FINDINGS: 20 patients (artesunate = 9, placebo = 11) completed the trial per protocol. Randomization groups were comparable clinically and for tumour characteristics. Apoptosis in > 7% of cells was seen in 67% and 55% of patients in artesunate and placebo groups, respectively. Using Bayesian analysis, the probabilities of an artesunate treatment effect reducing Ki67 and increasing CD31 expression were 0.89 and 0.79, respectively. During a median follow up of 42 months 1 patient in the artesunate and 6 patients in the placebo group developed recurrent CRC. INTERPRETATION: Artesunate has anti-proliferative properties in CRC and is generally well tolerated.
- Date of acceptance
- 2014
- Autoren
- Sanjeev Krishna
- Senthil Ganapathi
- Irina Chis Ster
- Mohamed EM Saeed
- Matt Cowan
- Caroline Finlayson
- Hajnalka Kovacsevics
- Herwig Jansen
- Peter G Kremsner
- Thomas Efferth
- Devinder Kumar
- Autoren-URL
- https://www.ncbi.nlm.nih.gov/pubmed/26137537
- DOI
- 10.1016/j.ebiom.2014.11.010
- Externe Identifier
- PubMed Central ID: PMC4484515
- ISSN
- 2352-3964
- Ausgabe der Veröffentlichung
- 1
- Zeitschrift
- EBioMedicine
- Schlüsselwörter
- Artesunate
- Colorectal cancer
- Dihydroartemisinin
- Ki67
- Neutropaenia
- Administration, Oral
- Aged
- Artemisinins
- Artesunate
- Biomarkers, Tumor
- Carcinoembryonic Antigen
- Colorectal Neoplasms
- Demography
- Double-Blind Method
- Female
- Humans
- Immunohistochemistry
- Ki-67 Antigen
- Male
- Pilot Projects
- Placebos
- Staining and Labeling
- Survival Analysis
- Treatment Outcome
- Sprache
- eng
- Country
- Netherlands
- Paginierung
- 82 - 90
- PII
- S2352-3964(14)00034-6
- Datum der Veröffentlichung
- 2015
- Status
- Published online
- Datum, an dem der Datensatz öffentlich gemacht wurde
- 2016
- Titel
- A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer.
- Sub types
- Journal Article
- Randomized Controlled Trial
- Ausgabe der Zeitschrift
- 2
Data source: PubMed
- Beziehungen:
- Property of